The use of Mexidol in intensive therapy of acute severe ischemic stroke

Authors:

Seryogin V.I., Dronova T.V.

GBU RO "Skopinskaya Central District Hospital", Ryazan Region, Russia

Place of publication:

Journal of Neurology and Psychiatry, 3, 2015; Ext. 2

The aim of the study was to evaluate the efficacy and safety of early use of Mexidol in the acute phase of severe ischemic stroke (IS). Material and methods. The study included 112 patients aged 35-85 years with severe IS. Patients were divided into two groups matched for gender and age. The study group (n=59) received Mexidol at a dose of 400 mg per day intravenously for 10 days and background therapy. The comparison group (n=53) received only background therapy. Results and discussion. In the study group, the proportion of favorable outcomes in severe IS, both with early and delayed treatment (according to the Rankin scale), was higher than in the comparison group, and the mortality rate was significantly lower. The results of the study showed that the use of Mexidol increases the effectiveness of therapy. The drug can be recommended for the treatment of patients with severe carotid IS.

Key words: severe ischemic stroke, mexidol, treatment.